Wang Jiao, Li Na, Xiao Cheng Kun, Han Shu Shu, Lu Min Jie, Lin Xiao Yi, Ren Ze Fang, Xu Lin
School of Public Health, Sun Yat-Sen University, 74 Zhongshan 2nd Road, Guangzhou, Guangdong Province, China.
Greater Bay Area Public Health Research Collaboration, Guangzhou, China.
Eur J Epidemiol. 2024 Dec;39(12):1401-1410. doi: 10.1007/s10654-024-01180-y. Epub 2024 Dec 16.
The Guangzhou Breast Cancer Study (GBCS) is a patient-based prospective cohort study designed to identify risk factors and underlying mechanisms for breast cancer (BC) incidence and prognosis, specifically addressing the need for individualized prevention in South China, where BC incidence is notably high. Based in Guangzhou, China, the GBCS began recruitment in 2008, comprises three complementary studies: the Guangzhou breast cancer cohort with 5471 breast cancer patients, a case-control study with 1551 cases and 1605 controls, and an immunohistochemistry (IHC) cohort with 1063 breast cancer patients. Participants are primarily aged 41-60 years. Cohort follow-up is conducted every three months in the first year, every six months in the second and third years, and annually thereafter. High follow-up rates have been achieved until 2023, with 73.5% for the Guangzhou breast cancer cohort and 98.6% for the IHC cohort still active. Baseline data collection included demographic characteristics and breast cancer risk factors, while follow-up data included survival, treatment details, disease history, occupational history, post-diagnostic lifestyle, and laboratory measures, including genetic markers, proteins, and environmental exposures. The study encourages global collaborations and invites interested researchers to contact the corresponding author at xulin27@ mail.sysu.edu.cn with specific research ideas or proposals.
广州乳腺癌研究（GBCS）是一项基于患者的前瞻性队列研究，旨在确定乳腺癌（BC）发病和预后的风险因素及潜在机制，特别针对中国南方对个性化预防的需求，该地区乳腺癌发病率显著较高。GBCS位于中国广州，于2008年开始招募，包括三项互补性研究：有5471名乳腺癌患者的广州乳腺癌队列、有1551例病例和1605名对照的病例对照研究，以及有1063名乳腺癌患者的免疫组织化学（IHC）队列。参与者主要年龄在41至60岁之间。队列随访在第一年每三个月进行一次，在第二和第三年每六个月进行一次，此后每年进行一次。截至2023年已实现高随访率，广州乳腺癌队列的随访率为73.5%，IHC队列仍有98.6%的随访率。基线数据收集包括人口统计学特征和乳腺癌风险因素，而随访数据包括生存情况、治疗细节、疾病史、职业史、诊断后的生活方式以及实验室检测指标，包括基因标志物、蛋白质和环境暴露情况。该研究鼓励全球合作，并邀请感兴趣的研究人员通过发送特定的研究想法或建议至xulin27@ mail.sysu.edu.cn与通讯作者联系。
